PMC6042494_01
Hematoxylin and Eosin staining of a metastatic specimen in left subphrenic space by endoscopic ultrasound-guided biopsy showing small cell carcinoma.. Note: The arrow indicates that the portion of the image at the base of the arrow has been magnified by x400.
ott-11-3943Fig1.jpg
PMC6042494_01_ott-11-3943Fig1.jpg
f1-ott-11-3943
TTF-1 (+), CD56 (+), and synaptophysin (+) (Figure 1). The tumor was refractory to two cycles of cytotoxic chemotherapy and docetaxel (Figure 2).
Computed tomography (CT) images showing treatment-related changes.
ott-11-3943Fig2.jpg
PMC6042494_01_ott-11-3943Fig2.jpg
f2-ott-11-3943
TTF-1 (+), CD56 (+), and synaptophysin (+) (Figure 1). The tumor was refractory to two cycles of cytotoxic chemotherapy and docetaxel (Figure 2). After cessation of chemotherapy, her disease progressed in July 2017 (Figure 2).
Computed tomography (CT) images showing differential response to single and combined therapies.
ott-11-3943Fig3b.jpg
PMC6042494_01_ott-11-3943Fig3b.jpg
f3-ott-11-3943
The metastatic subphrenic and liver masses presented dramatic progression despite subsequent cytotoxic chemotherapy with pemetrexed or etoposide/carboplatin from July to September 2017 (Figure 3). November 2017 (Figure 3). No significant adverse effects were observed with the combination chemotherapy.